Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Vascular Cell
Published in: Vascular Cell 1/2013

Open Access 01-12-2013 | Review

The role of tumor-associated macrophages in tumor vascularization

Authors: Chunqing Guo, Annicole Buranych, Devanand Sarkar, Paul B Fisher, Xiang-Yang Wang

Published in: Vascular Cell | Issue 1/2013

Login to get access

Abstract

Tumor vascularization is a highly complex process that involves the interaction between tumors and their surrounding stroma, as well as many distinct angiogenesis-regulating factors. Tumor associated macrophages (TAMs) represent one of the most abundant cell components in the tumor environment and key contributors to cancer-related inflammation. A large body of evidence supports the notion that TAMs play a critical role in promoting the formation of an abnormal tumor vascular network and subsequent tumor progression and invasion. Clinical and experimental evidence has shown that high levels of infiltrating TAMs are associated with poor patient prognosis and tumor resistance to therapies. In addition to stimulating angiogenesis during tumor growth, TAMs enhance tumor revascularization in response to cytotoxic therapy (e.g., radiotherapy), thereby causing cancer relapse. In this review, we highlight the emerging data related to the phenotype and polarization of TAMs in the tumor microenvironment, as well as the underlying mechanisms of macrophage function in the regulation of the angiogenic switch and tumor vascularization. Additionally, we discuss the potential of targeting pro-angiogenic TAMs, or reprograming TAMs toward a tumoricidal and angiostatic phenotype, to promote normalization of the tumor vasculature to enhance the outcome of cancer therapies.
Appendix
Available only for authorised users
Literature
1.
Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3: 401-410. 10.1038/nrc1093.PubMedCrossRef
2.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.PubMedCrossRef
3.
4.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016/S0092-8674(00)80108-7.PubMedCrossRef
5.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141: 39-51. 10.1016/j.cell.2010.03.014.PubMedCrossRef
6.
7.
Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604. 10.1016/j.immuni.2010.05.007.PubMedCrossRef
8.
9.
de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038/nrc1782.PubMedCrossRef
10.
11.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205.PubMedCrossRef
12.
Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008, 8: 618-631. 10.1038/nrc2444.PubMedCrossRef
13.
Baeriswyl V, Christofori G: The angiogenic switch in carcinogenesis. Seminars Cancer Biol. 2009, 19: 329-337. 10.1016/j.semcancer.2009.05.003.CrossRef
14.
Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006, 124: 263-266. 10.1016/j.cell.2006.01.007.PubMedCrossRef
15.
Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011, 19: 512-526. 10.1016/j.ccr.2011.02.005.PubMedCrossRef
16.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70: 5728-5739. 10.1158/0008-5472.CAN-09-4672.PubMedCrossRef
17.
Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M: A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 2009, 114: 901-914. 10.1182/blood-2009-01-200931.PubMedCrossRef
18.
Mantovani A, Allavena P, Sica A: Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004, 40: 1660-1667. 10.1016/j.ejca.2004.03.016.PubMedCrossRef
19.
Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66: 605-612. 10.1158/0008-5472.CAN-05-4005.PubMedCrossRef
20.
Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A: Macrophage polarization in tumour progression. Seminars Cancer Biol. 2008, 18: 349-355. 10.1016/j.semcancer.2008.03.004.CrossRef
21.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23: 549-555. 10.1016/S1471-4906(02)02302-5.PubMedCrossRef
22.
Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006, 107: 2112-2122. 10.1182/blood-2005-01-0428.PubMedCrossRef
23.
Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE: Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood. 2009, 113: 3139-3146. 10.1182/blood-2008-12-172825.PubMedCentralPubMedCrossRef
24.
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW: Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2010, 184: 702-712. 10.4049/jimmunol.0902360.PubMedCentralPubMedCrossRef
25.
Lamagna C, Aurrand-Lions M, Imhof BA: Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006, 80: 705-713. 10.1189/jlb.1105656.PubMedCrossRef
26.
Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A, Mazzone M, Lyle R, Naldini L, De Palma M: miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep. 2012, 1: 141-154. 10.1016/j.celrep.2011.12.005.PubMedCrossRef
27.
Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM: Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012, 109: 2796-2801. 10.1073/pnas.1104303108.PubMedCentralPubMedCrossRef
28.
Heusinkveld M, van der Burg SH: Identification and manipulation of tumor associated macrophages in human cancers. J Translational Med. 2011, 9: 216-10.1186/1479-5876-9-216.CrossRef
29.
Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196: 254-265. 10.1002/path.1027.PubMedCrossRef
30.
Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA, Gribben JG: Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood. 2010, 115: 5053-5056. 10.1182/blood-2009-11-253260.PubMedCentralPubMedCrossRef
31.
Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56: 4625-4629.PubMed
32.
Chen P, Bonaldo P: Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol. 2013, 301: 1-35.PubMedCrossRef
33.
Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M: Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010, 101: 1913-1919. 10.1111/j.1349-7006.2010.01614.x.PubMedCrossRef
34.
Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, Ito Y, Inamura T, Ikezaki K, Fukui M, et al: Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999, 5: 1107-1113.PubMed
35.
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011, 475: 222-225. 10.1038/nature10138.PubMedCentralPubMedCrossRef
36.
Ruffell B, Affara NI, Coussens LM: Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012, 33: 119-126. 10.1016/j.it.2011.12.001.PubMedCentralPubMedCrossRef
37.
Squadrito ML, De Palma M: Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med. 2011, 32: 123-145. 10.1016/j.mam.2011.04.005.PubMedCrossRef
38.
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR: “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Experiment Med. 2008, 205: 1261-1268. 10.1084/jem.20080108.CrossRef
39.
Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, et al: Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010, 70: 4840-4849. 10.1158/0008-5472.CAN-10-0269.PubMedCrossRef
40.
Bergenfelz C, Medrek C, Ekstrom E, Jirstrom K, Janols H, Wullt M, Bredberg A, Leandersson K: Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol. 2012, 188: 5448-5458. 10.4049/jimmunol.1103378.PubMedCrossRef
41.
Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell metabolism. 2007, 6: 137-143. 10.1016/j.cmet.2007.06.010.PubMedCrossRef
42.
Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, et al: Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood. 2012, 119: 411-421. 10.1182/blood-2011-02-339911.PubMedCrossRef
43.
Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA: Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol. 2013, 190: 2984-2993. 10.4049/jimmunol.1201650.PubMedCentralPubMedCrossRef
44.
Zumsteg A, Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol. 2009, 21: 60-70. 10.1097/CCO.0b013e32831bed7e.PubMedCrossRef
45.
Sunderkotter C, Beil W, Roth J, Sorg C: Cellular events associated with inflammatory angiogenesis in the mouse cornea. Am J Pathol. 1991, 138: 931-939.PubMedCentralPubMed
46.
Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, Fong GH, Gabril MY, Moussa M, Chin JL: Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res. 2002, 8: 471-480.PubMed
47.
Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193: 727-740. 10.1084/jem.193.6.727.PubMedCentralPubMedCrossRef
48.
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66: 11238-11246. 10.1158/0008-5472.CAN-06-1278.PubMedCrossRef
49.
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY: Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010, 16: 3420-3430. 10.1158/1078-0432.CCR-09-2904.PubMedCrossRef
50.
Ojalvo LS, King W, Cox D, Pollard JW: High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol. 2009, 174: 1048-1064. 10.2353/ajpath.2009.080676.PubMedCentralPubMedCrossRef
51.
Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000, 192: 150-158. 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G.PubMedCrossRef
52.
Lin EY, Pollard JW: Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67: 5064-5066. 10.1158/0008-5472.CAN-07-0912.PubMedCrossRef
53.
Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, Pollard JW: Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2007, 1: 288-302. 10.1016/j.molonc.2007.10.003.PubMedCentralPubMedCrossRef
54.
Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008, 456: 814-818. 10.1038/nature07445.PubMedCentralPubMedCrossRef
55.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery. 2011, 1: 54-67. 10.1158/2159-8274.CD-10-0028.PubMedCentralPubMedCrossRef
56.
Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, Frasca D, Koker M, Konig K, Meder L, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013, 123: 1732-1740. 10.1172/JCI65385.PubMedCentralPubMedCrossRef
57.
Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW: Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol. 2006, 80: 1183-1196. 10.1189/jlb.0905495.PubMedCrossRef
58.
Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007, 131: 463-475. 10.1016/j.cell.2007.08.038.PubMedCrossRef
59.
Brecht K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T, Fleming I, Geisslinger G, Brune B: Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 2011, 25: 2408-2417. 10.1096/fj.10-179473.PubMedCrossRef
60.
Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y: Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Ca Res. 2011, 17: 7230-7239. 10.1158/1078-0432.CCR-11-1354.CrossRef
61.
Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene. 2013, in press
62.
Mason SD, Joyce JA: Proteolytic networks in cancer. Trends Cell Biol. 2011, 21: 228-237. 10.1016/j.tcb.2010.12.002.PubMedCrossRef
63.
Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA: IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010, 24: 241-255. 10.1101/gad.1874010.PubMedCentralPubMedCrossRef
64.
Small DM, Burden RE, Jaworski J, Hegarty SM, Spence S, Burrows JF, McFarlane C, Kissenpfennig A, McCarthy HO, Johnston JA, et al: Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int J Cancer. 2013, 133: 2102-2112. 10.1002/ijc.28238.PubMedCrossRef
65.
66.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000, 2: 737-744. 10.1038/35036374.PubMedCentralPubMedCrossRef
67.
Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000, 103: 481-490. 10.1016/S0092-8674(00)00139-2.PubMedCentralPubMedCrossRef
68.
Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004, 114: 623-633. 10.1172/JCI200422087.PubMedCentralPubMedCrossRef
69.
Ahn GO, Brown JM: Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer cell. 2008, 13: 193-205. 10.1016/j.ccr.2007.11.032.PubMedCentralPubMedCrossRef
70.
Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008, 13: 206-220. 10.1016/j.ccr.2008.01.034.PubMedCentralPubMedCrossRef
71.
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL: Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Pathol. 1997, 182: 414-420. 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q.PubMedCrossRef
72.
Goto H, Kohno K, Sone S, Akiyama S, Kuwano M, Ono M: Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res. 2001, 61: 469-473.PubMed
73.
Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL: Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res. 2003, 63: 527-533.PubMed
74.
Kawahara A, Hattori S, Akiba J, Nakashima K, Taira T, Watari K, Hosoi F, Uba M, Basaki Y, Koufuji K, et al: Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Oncology reports. 2010, 24: 405-415.PubMedCrossRef
75.
Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004, 64: 5378-5384. 10.1158/0008-5472.CAN-04-0961.PubMedCrossRef
76.
Muramatsu M, Yamamoto S, Osawa T, Shibuya M: Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 2010, 70: 8211-8221. 10.1158/0008-5472.CAN-10-0202.PubMedCrossRef
77.
Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, Mueller MM: Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol. 2012, 227: 17-28. 10.1002/path.3989.PubMedCrossRef
78.
Serbina NV, Pamer EG: Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006, 7: 311-317.PubMedCrossRef
79.
Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001, 92: 1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K.PubMedCrossRef
80.
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000, 6: 3282-3289.PubMed
81.
Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004, 104: 2224-2234. 10.1182/blood-2004-03-1109.PubMedCrossRef
82.
Zhang J, Lu Y, Pienta KJ: Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010, 102: 522-528. 10.1093/jnci/djq044.PubMedCentralPubMedCrossRef
83.
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ: CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biologic Chem. 2009, 284: 34342-34354. 10.1074/jbc.M109.042671.CrossRef
84.
85.
Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004, 10: 858-864. 10.1038/nm1075.PubMedCrossRef
86.
Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE: TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest. 2011, 121: 1969-1973. 10.1172/JCI44562.PubMedCentralPubMedCrossRef
87.
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010, 120: 694-705. 10.1172/JCI40283.PubMedCentralPubMedCrossRef
88.
Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG: Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer research. 2010, 70: 5679-5685. 10.1158/0008-5472.CAN-09-4446.PubMedCentralPubMedCrossRef
89.
Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P: The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2011, 117: 88-97. 10.1182/blood-2009-12-258186.PubMedCrossRef
90.
Fischer C, Mazzone M, Jonckx B, Carmeliet P: FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer. 2008, 8: 942-956. 10.1038/nrc2524.PubMedCrossRef
91.
Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, et al: Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010, 141: 178-190. 10.1016/j.cell.2010.02.039.PubMedCrossRef
92.
Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al: HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011, 19: 31-44. 10.1016/j.ccr.2010.11.009.PubMedCrossRef
93.
Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008, 118: 3367-3377. 10.1172/JCI35213.PubMedCentralPubMedCrossRef
94.
Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M: Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012, 103: 2165-2172. 10.1111/cas.12015.PubMedCrossRef
95.
Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, et al: Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011, 71: 6601-6610. 10.1158/0008-5472.CAN-11-1217.PubMedCentralPubMedCrossRef
96.
Sevilla L, Aperlo C, Dulic V, Chambard JC, Boutonnet C, Pasquier O, Pognonec P, Boulukos KE: The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-xL-dependent mechanism. Mol Cell Biol. 1999, 19: 2624-2634.PubMedCentralPubMedCrossRef
97.
Wei G, Guo J, Doseff AI, Kusewitt DF, Man AK, Oshima RG, Ostrowski MC: Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. J Immunol. 2004, 173: 1374-1379.PubMedCrossRef
98.
Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, Rosol TJ, Fernandez S, Huang K, Leone G, Ostrowski MC: An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res. 2010, 70: 1323-1333. 10.1158/0008-5472.CAN-09-1474.PubMedCentralPubMedCrossRef
99.
Wu H, Xu JB, He YL, Peng JJ, Zhang XH, Chen CQ, Li W, Cai SR: Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J Surg Oncol. 2012, 106: 462-468. 10.1002/jso.23110.PubMedCrossRef
100.
Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, Liang TB: Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012, 72: 1363-1372. 10.1158/0008-5472.CAN-11-2684.PubMedCrossRef
101.
Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, Machein MR: Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008, 68: 7342-7351. 10.1158/0008-5472.CAN-07-6241.PubMedCrossRef
102.
Yang Y, Sun M, Wang L, Jiao B: HIFs, angiogenesis, and cancer. J Cell Biochem. 2013, 114: 967-974. 10.1002/jcb.24438.PubMedCrossRef
103.
Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ: Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009, 15: 527-538. 10.1016/j.ccr.2009.04.010.PubMedCentralPubMedCrossRef
104.
Lewis C, Murdoch C: Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005, 167: 627-635. 10.1016/S0002-9440(10)62038-X.PubMedCentralPubMedCrossRef
105.
Shen Z, Kauttu T, Seppanen H, Vainionpaa S, Ye Y, Wang S, Mustonen H, Puolakkainen P: Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol. 2012, 29: 2718-2726. 10.1007/s12032-012-0212-1.PubMedCrossRef
106.
Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005, 24: 5552-5560. 10.1038/sj.onc.1208719.PubMedCrossRef
107.
Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H: Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008, 6: 1099-1105. 10.1158/1541-7786.MCR-07-2177.PubMedCentralPubMedCrossRef
108.
Papadakis AI, Paraskeva E, Peidis P, Muaddi H, Li S, Raptis L, Pantopoulos K, Simos G, Koromilas AE: eIF2{alpha} Kinase PKR modulates the hypoxic response by Stat3-dependent transcriptional suppression of HIF-1{alpha}. Cancer Res. 2010, 70: 7820-7829. 10.1158/0008-5472.CAN-10-0215.PubMedCrossRef
109.
Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH: STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005, 19: 1296-1298.PubMed
110.
Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O: Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res. 2007, 13: 6459-6468. 10.1158/1078-0432.CCR-07-1104.PubMedCrossRef
111.
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, et al: IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011, 17: 2538-2548. 10.1158/1078-0432.CCR-10-3314.PubMedCrossRef
112.
De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003, 9: 789-795. 10.1038/nm871.PubMedCrossRef
113.
Geissmann F, Auffray C, Palframan R, Wirrig C, Ciocca A, Campisi L, Narni-Mancinelli E, Lauvau G: Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol. 2008, 86: 398-408. 10.1038/icb.2008.19.PubMedCrossRef
114.
MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, et al: An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010, 116: 3955-3963. 10.1182/blood-2010-02-266296.PubMedCrossRef
115.
De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005, 8: 211-226. 10.1016/j.ccr.2005.08.002.PubMedCrossRef
116.
Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L: Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007, 109: 5276-5285. 10.1182/blood-2006-10-053504.PubMedCrossRef
117.
Murdoch C, Tazzyman S, Webster S, Lewis CE: Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. 2007, 178: 7405-7411.PubMedCrossRef
118.
Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, Miyazaki M, Sakakibara M, Hiramatsu N, Kasahara A, et al: TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology. 2013, 57: 1416-1425. 10.1002/hep.25965.PubMedCrossRef
119.
Augustin HG, Koh GY, Thurston G, Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009, 10: 165-177. 10.1038/nrm2639.PubMedCrossRef
120.
Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y, Lewis CE: Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70: 5270-5280. 10.1158/0008-5472.CAN-10-0012.PubMedCrossRef
121.
122.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012, 12: 253-268. 10.1038/nri3175.PubMedCentralPubMedCrossRef
123.
Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004, 6: 409-421. 10.1016/j.ccr.2004.08.031.PubMedCrossRef
124.
Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007, 117: 1155-1166. 10.1172/JCI31422.PubMedCentralPubMedCrossRef
125.
Kusmartsev S, Gabrilovich DI: STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005, 174: 4880-4891.PubMedCrossRef
126.
Kusmartsev S, Nagaraj S, Gabrilovich DI: Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005, 175: 4583-4592.PubMedCentralPubMedCrossRef
127.
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007, 179: 977-983.PubMedCrossRef
128.
Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al: HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010, 207: 2439-2453. 10.1084/jem.20100587.PubMedCentralPubMedCrossRef
129.
He H, Xu J, Warren CM, Duan D, Li X, Wu L, Iruela-Arispe ML: Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood. 2012, 120: 3152-3162. 10.1182/blood-2012-04-422758.PubMedCentralPubMedCrossRef
130.
Carmeliet P, Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Dis. 2011, 10: 417-427. 10.1038/nrd3455.CrossRef
131.
132.
Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, et al: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007, 450: 825-831. 10.1038/nature06348.PubMedCrossRef
133.
Shojaei F, Ferrara N: Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 2008, 68: 5501-5504. 10.1158/0008-5472.CAN-08-0925.PubMedCrossRef
134.
Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006, 95: 272-281. 10.1038/sj.bjc.6603240.PubMedCentralPubMedCrossRef
135.
Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010, 115: 1461-1471. 10.1182/blood-2009-08-237412.PubMedCentralPubMedCrossRef
136.
Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006, 66: 4349-4356. 10.1158/0008-5472.CAN-05-3523.PubMedCrossRef
137.
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al: Role of macrophage targeting in the antitumor activity of trabectedin. Cancer cell. 2013, 23: 249-262. 10.1016/j.ccr.2013.01.008.PubMedCrossRef
138.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003, 300: 1155-1159. 10.1126/science.1082504.PubMedCrossRef
139.
Shiao SL, Coussens LM: The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010, 15: 411-421. 10.1007/s10911-010-9194-9.PubMedCentralPubMedCrossRef
140.
Milas L, Wike J, Hunter N, Volpe J, Basic I: Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res. 1987, 47: 1069-1075.PubMed
141.
Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM: Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010, 107: 8363-8368. 10.1073/pnas.0911378107.PubMedCentralPubMedCrossRef
142.
Chiang CS, Fu SY, Wang SC, Yu CF, Chen FH, Lin CM, Hong JH: Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012, 2: 89-PubMedCentralPubMedCrossRef
143.
Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013, 73: 2782-2794. 10.1158/0008-5472.CAN-12-3981.PubMedCentralPubMedCrossRef
144.
De Palma M, Lewis CE: Cancer: Macrophages limit chemotherapy. Nature. 2011, 472: 303-304. 10.1038/472303a.PubMedCrossRef
145.
Szlosarek PW, Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4: 565-573. 10.1016/S1470-2045(03)01196-3.PubMedCrossRef
146.
Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006, 176: 5023-5032.PubMedCrossRef
147.
Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, Trinchieri G, Colombo MP, Chiodoni C: Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res. 2010, 70: 7764-7775. 10.1158/0008-5472.CAN-10-0471.PubMedCrossRef
148.
De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S, et al: Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008, 14: 299-311. 10.1016/j.ccr.2008.09.004.PubMedCrossRef
149.
Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al: FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010, 17: 121-134. 10.1016/j.ccr.2009.12.019.PubMedCentralPubMedCrossRef
150.
Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307: 58-62. 10.1126/science.1104819.PubMedCrossRef
151.
Garber K: Targeting vessel abnormalization in cancer. J Natl Cancer Inst. 2007, 99: 991-995. 10.1093/jnci/djm056.PubMedCrossRef
152.
De Bock K, Cauwenberghs S, Carmeliet P: Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev. 2011, 21: 73-79. 10.1016/j.gde.2010.10.008.PubMedCrossRef
153.
Squadrito ML, De Palma MD: Macrophage regulation of tumor angiogenesis: Implications for cancer therapy. Mol Aspects Med. 2011, 32: 123-145. 10.1016/j.mam.2011.04.005.PubMedCrossRef
154.
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011, 331: 1612-1616. 10.1126/science.1198443.PubMedCentralPubMedCrossRef
Metadata
Title
The role of tumor-associated macrophages in tumor vascularization
Authors
Chunqing Guo
Annicole Buranych
Devanand Sarkar
Paul B Fisher
Xiang-Yang Wang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Vascular Cell / Issue 1/2013
Electronic ISSN: 2045-824X
DOI
https://doi.org/10.1186/2045-824X-5-20

Other articles of this Issue 1/2013

Vascular Cell 1/2013 Go to the issue

Research

Cardiac angiogenesis directed by stable Hypoxia Inducible Factor-1

Research

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

Research

Notch4 is required for tumor onset and perfusion

Review

A brief primer on microRNAs and their roles in angiogenesis

Review

The importance of microglia in the development of the vasculature in the central nervous system

Review

The effects of radiation on angiogenesis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits